Zhu Cui1, Zachary Merritt1, Andrei Assa2, Hashim Mustehsan1, Erica Chung1, Sichen Liu1, Anand Kumthekar3, Bibi Ayesha4, Margaret McCort4, Leonidas Palaiodimos2, Sarah Baron2, Yelena Averbukh2, William Southern2, Shitij Arora2. 1. Division of General Internal Medicine, Department of Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York. 2. Division of Hospital Medicine, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York. 3. Division of Rheumatology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York. 4. Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York.
Abstract
BACKGROUND: Corticosteroids may be beneficial in a subset of patients with coronavirus disease 2019 (COVID-19), but predictors of therapeutic response remain unknown. C-reactive protein (CRP) is a routinely measured biomarker, and reduction in its levels after initiation of therapy may predict inpatient mortality. METHODS: In this retrospective cohort study, the charts of patients who were admitted to Montefiore Medical Center between March 10, 2020, and May 2, 2020 for the management of COVID-19 were examined. Of all patients who met inclusion criteria, patients who received corticosteroid treatment were categorized as CRP responders (≥50% CRP level reduction) and CRP nonresponders (<50% CRP level reduction) based on change in CRP within 72 hours of corticosteroid treatment initiation. The outcomes of interest were two-fold: (1) CRP response after treatment with corticosteroid, and (2) differences in mortality among patients with CRP response compared those without. RESULTS: Of 2,707 patients admitted during the study period, 324 received corticosteroid treatment. Of patients who received corticosteroid treatment, CRP responders had reduced risk of death compared with risk among CRP nonresponders (25.2% vs 47.8%; unadjusted odds ratio [OR], 0.37; 95% CI, 0.21-0.65; P <.001). This effect remained strong and significant after adjustment for potential confounders (adjusted OR, 0.27; 95% CI, 0.14-0.54; P <.001). CONCLUSION: Reduction in CRP by 50% or more within 72 hours of initiating corticosteroid therapy potentially predicts inpatient mortality. This may serve as an early biomarker of response to corticosteroid therapy in patients with COVID-19.
BACKGROUND: Corticosteroids may be beneficial in a subset of patients with coronavirus disease 2019 (COVID-19), but predictors of therapeutic response remain unknown. C-reactive protein (CRP) is a routinely measured biomarker, and reduction in its levels after initiation of therapy may predict inpatient mortality. METHODS: In this retrospective cohort study, the charts of patients who were admitted to Montefiore Medical Center between March 10, 2020, and May 2, 2020 for the management of COVID-19 were examined. Of all patients who met inclusion criteria, patients who received corticosteroid treatment were categorized as CRP responders (≥50% CRP level reduction) and CRP nonresponders (<50% CRP level reduction) based on change in CRP within 72 hours of corticosteroid treatment initiation. The outcomes of interest were two-fold: (1) CRP response after treatment with corticosteroid, and (2) differences in mortality among patients with CRP response compared those without. RESULTS: Of 2,707 patients admitted during the study period, 324 received corticosteroid treatment. Of patients who received corticosteroid treatment, CRP responders had reduced risk of death compared with risk among CRP nonresponders (25.2% vs 47.8%; unadjusted odds ratio [OR], 0.37; 95% CI, 0.21-0.65; P <.001). This effect remained strong and significant after adjustment for potential confounders (adjusted OR, 0.27; 95% CI, 0.14-0.54; P <.001). CONCLUSION: Reduction in CRP by 50% or more within 72 hours of initiating corticosteroid therapy potentially predicts inpatient mortality. This may serve as an early biomarker of response to corticosteroid therapy in patients with COVID-19.
Authors: Sweta Chekuri; Wendy A Szymczak; D Yitzchak Goldstein; Priya Nori; Rebecca Marrero Rolon; Brian Spund; Sumeet Singh-Tan; Laurel Mohrmann; Andrei Assa; William N Southern; Sarah W Baron Journal: J Antimicrob Chemother Date: 2021-09-23 Impact factor: 5.790
Authors: Rohit Baslas; Dorina-Gabriela Condurache; Ambikesh Jayal; Matthew Colquhoun; Jacob Frederik de Wolff Journal: Postgrad Med J Date: 2022-04-15 Impact factor: 4.973
Authors: Raquel Carbonell; Silvia Urgelés; Melina Salgado; Alejandro Rodríguez; Luis Felipe Reyes; Yuli V Fuentes; Cristian C Serrano; Eder L Caceres; María Bodí; Ignacio Martín-Loeches; Jordi Solé-Violán; Emili Díaz; Josep Gómez; Sandra Trefler; Montserrat Vallverdú; Josefa Murcia; Antonio Albaya; Ana Loza; Lorenzo Socias; Juan Carlos Ballesteros; Elisabeth Papiol; Lucía Viña; Susana Sancho; Mercedes Nieto; M Del; Carmen Lorente; Oihane Badallo; Virginia Fraile; Fernando Arméstar; Angel Estella; Paula Abanses; Isabel Sancho; Neus Guasch; Gerard Moreno Journal: J Infect Date: 2022-06-30 Impact factor: 38.637